manisha-tripathi
Manisha Tripathi, Ph.D.
Assistant Professor of Cell Biology and Biochemistry

Texas Tech University Health Sciences Center
Lubbock, Texas, USA
Phone: (806) 743-4140, Fax: 806-743-2990
E-mail: [email protected]

Education

1996 - 1999 B.Sc. Chemistry, Zoology, Botany Awadhesh Pratap Singh University, Rewa, India
1999 - 2001 M.Sc. Biotechnology Barkatullah University, Bhopal, India
2004 - 2011 Ph.D. Cancer Biology Vanderbilt University School of Medicine, Nashville, TN, USA
2011 - 2016 Post-Doctoral Training The role of tumor microenvironment in prostate cancer progression Cedars-Sinai Medical Center, Los Angeles, CA, USA

Biography

Manisha Tripathi is an Assistant Professor in the Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock. Dr. Tripathi received her Ph.D. from the Department of Cancer Biology, Vanderbilt University, Nashville. Dr. Tripathi did her Post-Doctoral training at Cedars-Sinai Medical Center, Los Angeles. Dr. Tripathi’s research focuses on the cross-talk between the epithelia and cells of tumor microenvironment in Prostate Cancer progression.


Research Interest

Role of the Tumor Microenvironment (TME) including immune cells in Prostate Cancer progression, Cross-talk between the epithelia and Cancer Associated Fibroblasts (CAFs) in Castrate Resistant Prostate Cancer (CRPC), Role of the TME in mediating drug efficacy in Prostate Cancer, Role of TME in drug resistance to androgen deprivation therapy (ADT) in Prostate Cancer


Scientific Activities

2018 - present Assistant Professor (Tenure Track), Dept. of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
2016-2018 Project Scientist, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
2011-2016 Postdoctoral Scientist, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
2004-2011 Graduate Student, Vanderbilt University School of Medicine, Nashville, TN, USA.
2002-2003 Project Assistant, National Institute of Immunology, New Delhi, India.
2000-2001 Project Trainee, National Institute of Immunology, New Delhi, India.
Honors/Awards

2018: Recognition for exceptional effort towards teamwork from the Department of Neuroscience, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
2017: Award of Recognition for Outstanding Performance, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
2015: Poster Presentation Award, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
2009: Poster Presentation Award, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
2008: Travel Award, Society for Basic Urologic Research, USA.
2004: Fellowship, Interdisciplinary Graduate Program in Biomedical Sciences, Vanderbilt University, Nashville, TN, USA.
2000: Dissertation Research Scholarship, Barkatullah University, Bhopal, M.P., India.
1999: Gold Medal, Awadhesh Pratap Singh University, Rewa, M.P., India.

Membership

American Association for Cancer Research (AACR) USA
Society for Basic Urologic Research (SBUR) USA


Publications

  1. Reichel D, Tripathi M, Perez JM. Biological Effects of Nanoparticles on Macrophage Polarization in the Tumor Microenvironment. Nanotheranostics. 2019 Jan 1;3(1):66-88.
  2. Cavassani K, Rebecca M, David H, Chen J, Alexander M, Tripathi M, Martins G, Timothy C, You S, Hogaboam C, Bhowmick N, Posadas E. Circulating monocytes from prostate cancer patients promote invasion and motility of epithelial cells. Cancer Med. 2018 Sep; 7(9): 4639–4649.
  3. Kato M, Placencio VR, Madhav A, Haldar S, Tripathi M, Billet S, Mishra R, Smith B, Rohena-Rivera K, Agarwal P, Duong F, Angara B, Hickok D, Liu Z, Bhowmick N. Heterogeneous cancer associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner. Oncogene. 2018 Sep 3. doi: 10.1038/s41388-018-0461-3.
  4. Mishra R, Haldar S, Placencio V, Madhav A, Rohena-Rivera K, Agarwal P, Duong F, Angara B, Tripathi M, Liu Z, Gottlieb RA, Wagner S, Posadas EM, Bhowmick NA. Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming. J Clin Invest. 2018 Oct 1;128(10):4472-4484.
  5. Tripathi M.*, Nandana S.*, Billet S., Cavassani K., Chung L.W.K., Posadas E.M., Bhowmick N.A. Modulation of cabozantinib efficacy by the prostate tumor microenvironment. Manuscript Accepted in Oncotarget, Oncotarget. 2017 Sep 23;8(50):87891-87902. (*contributed equally).
  6. Nandana S.*, Tripathi M.*, Duan P., Chu C.Y., Mishra R., Liu C., Jin R., Yamashita H., Zayzafoon M., Bhowmick N.A., Zhau H.E., Matusik R.J. and Chung L.W.K. Bone metastasis of prostate cancer can be therapeutically targeted at the TBX2-WNT signaling axis. Cancer Research, 77(6):1331-1344; Mar 15, 2017 (*contributed equally).
  7. Haldar S., Dru C., Mishra R., Tripathi M., Angara B., Duong F., Fernandez A., Arditi M., Bhowmick N.A. Histone deacetylase inhibitors mediate DNA damage repair in ameliorating hemorrhagic cystitis. Scientific Reports, 6: 39257; DOI: 10.1038/srep39257, 2016.
  8. Qi J., Tripathi M., Mishra R., Sahgal N., Fazil L., Ettinger S., Placzek W.J., Claps G., Chung L.W.K., Bowtell D., Gleave M., Bhowmick N.A., and Ronai Z.A. The E3 Ubiquitin Ligase Siah2 Contributes to Castration-Resistant Prostate Cancer by Regulation of Androgen Receptor Transcriptional Activity. Cancer Cell, Volume 23, Issue 3: March 18, 2013.
  9. Tripathi M., Billet S., and Bhowmick N.A. Understanding the role of stromal fibroblasts in cancer progression. Cell Adhesion & Migration. 1; 6(3): 231-5, May 2012.
  10. Tripathi M., Potdar A., Yamashita H., Weidow B., Cummings P.T., Kirchhofer D., and Quaranta V. Laminin-332 cleavage by Matriptase alters motility parameters of prostate cancer cells. The Prostate, 1; 71 (2): 184-96 Feb, 2011.
  11. Yamashita H., Tripathi M., Jourquin J., Kam Y., Liu S., Weidow B., and Quaranta V. Lysophosphatidic acid upregulates laminin-332 expression during A431 cell colony dispersal. Journal of Oncology, Article ID 107075, Aug, 2010.
  12. Yamashita H., Tripathi M., Harris M., Ronca F., Liu S, and Quaranta V. A recombinant fragment of laminin-332 directs integrin α3β1-dependent cell binding, spreading, and migration. Biomaterials, 31 (19): 5110-21, Mar 26, 2010.
  13. Yamashita H., Shang M., Tripathi M., Jourquin J., Liu S., Weidow B., and Quaranta V. Epitope Mapping of Function-blocking Monoclonal Antibody CM6 Suggests a "Weak" Integrin Binding Site on the Laminin-332 LG2 Domain. Journal of Cellular Physiology 223 (3): 541-548, Mar 18, 2010.
  14. Tripathi M., Nandana S., Yamashita H., Kirchhofer D., and Quaranta V. Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression. Journal of Biological Chemistry, 283 (45): 30576-84. Nov, 2008.
  15. Dey P.*, Tripathi M.*, and Batra J.K. Involvement of loops L2 and L4 of ribonucleolytic toxin restrictocin in its functional activity. Protein and Peptide Letters, 14: 125-129, 2007 (*contributed equally).
Book Chapters
  1. Jourquin J., Tripathi M., Guess C. and Quaranta V. “Laminins and cancer progression” in “Cell- Extracellular Matrix Interactions and Cancer.” Zent R and Pozzi A (editors), Springer-Verlag New York (Publisher) 2009.
Abstracts
  1. Cavassani K, Rebecca M, David H, Chen J, Alexander M, Tripathi M, Martins G, Timothy C, You S, Hogaboam C, Bhowmick N, Posadas E. Monocyte-produced Chitinase-3-like 1 is a driver of metastatic behavior in prostate cancer patients. Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. Cancer Research 78 (13 Supplement), 5208-5208.
  2. EM Posadas, JF Chen, M Tripathi, YT Lu, A Montes, A Go, A Ureno, Cavassani K, Sievert M, Rogatko A, Limvorasak S, Oppenheim A, Moldawer N, Chung LWK, Bhowmick N,Tseng H, Figlin R. Circulating tumor cell subsets and macrophage polarization to predict efficacy of cabozantinib in advanced prostate cancer with visceral metastases. American Society of Clinical Oncology Annual Meeting: May 20 2017, Journal of Clinical Oncology 35 (15_suppl), 5031-503.
  3. Tripathi M., Nandana S., Billet S., Posadas E.M., Chung L.W.K., and Bhowmick N.A. Microenvironment mediates the efficacy of cabozantinib in prostate cancer. AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. Cancer Research 76 (14 Supplement), LB-274-LB-274.
  4. Tripathi M., Nandana S., Huang J., Kato M., Chung L.W.K., Xin L. and Bhowmick N.A. Reciprocal prostate cancer signaling with its microenvironment mediates castrate resistant disease progression. Cancer Research 76 (15 Supplement), PR06-PR06 Published 1 August 2016 Abstracts: AACR Special Conference: The Function of Tumor Microenvironment in Cancer Progression; January 7-10, 2016; San Diego, CA.
  5. Nandana S., Tripathi M., Duan P., Chu C., Zhau H.E., Matusik R.J. and Chung L.W.K. Blocking endogenous TBX2 abrogates prostate cancer bone metastasis through WNT signaling. AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. Cancer Research 76 (14 Supplement), 4131-4131.
  6. Tripathi M., Nandana S., Billet S., Posadas E.M., Chung L.W.K., and Bhowmick N.A. Microenvironment mediates the efficacy of cabozantinib in prostate cancer. Annual Research Day, Cedars-Sinai Medical Center, Feb 2016, Los Angeles, CA.
  7. Nandana S., Tripathi M., Duan P., Chu C., Mishra R., Liu C., Jin R., Yamashita H., Zayzafoon M., Bhowmick N.A., Zhau H.E., Matusik R.J. and Chung L.W.K. TBX2-WNT signaling axis – a new therapeutic target for prostate cancer bone metastasis. The Stem Cell Niche and Cancer Microenvironment Symposium, Cedars-Sinai Medical Center, Nov 2015, Los Angeles, CA.
  8. Tripathi M., Nandana S., Billet S., Chung L.W.K., Posadas E.M. and Bhowmick N.A. Microenvironment mediates the efficacy of cabozantinib in prostate cancer. The Stem Cell Niche and Cancer Microenvironment Symposium, Cedars-Sinai Medical Center, Nov 2015, Los Angeles, CA.
  9. Qi J, Tripathi M., Sahgal N., Fazil L., Ettinger S., Placzek W.J., Claps G., Chung L.W.K., Bowtell D., Gleave M, Bhowmick N, and Ronai Z. The E3 ubiquitin ligase Siah2 regulates the androgen receptor activity and contributes to castration-resistant prostate cancer. AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. Cancer Research 73 (8 Supplement), 5456-5456.
  10. Nandana S., Tripathi M., Chu C., Bhowmick N.A., Matusik R.J. and Chung L.W.K. Blocking endogenous TBX2 expression in PC3 prostate cancer cells abrogates bone metastasis in a xenograft mouse model. AACR Special Conference on Tumor Invasion and Metastasis, Jan 2013, San Diego, CA. Cancer Research 73 (3 Supplement), C23-C23.
  11. Tripathi M., Jackson R. and Bhowmick N.A. Role of stromal factors in the maintenance of progenitor cells in prostate cancer. Fourth Annual Cancer Institute Research Poster Presentation, Cedars-Sinai Medical Center, June 2012, Los Angeles, CA.
  12. Mishra R., Biondi S., Tripathi M. and Neil Bhowmick N.A. Role of epigenetics modification in stromal induction of prostate cancer progression. Society for Basic Urologic Research (SBUR), November 2012, Miami, FL.
  13. Tripathi M., Nandana S., Yamashita H., Potdar A., Ganesan R., Weidow B., Cummings P., Kirchhofer D., and Quaranta V. Proteolytic processing of laminin-332 by hepsin and matriptase and its role in prostate cancer progression. Department of Defense Prostate Cancer IMPACT Meeting, March 2011, Orlando, FL.
  14. Tripathi M., Jackson R. and Bhowmick N.A. Role of stromal factors in the maintenance of progenitor cells in prostate cancer. Society for Basic Urologic Research (SBUR), November 2011, Las Vegas, NV.
  15. Tripathi M., Potdar A., Yamashita H., Weidow B., Cummings P.T., Daniel Kirchhofer, and Quaranta V. Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells. Symposium on Basement Membranes in Tissue Development and Regeneration, Center for Matrix Biology, Vanderbilt University, July 2010, Nashville, TN.
  16. Tripathi M., Potdar A., Yamashita H., Weidow B., Cummings P.T., Kirchhofer D., and Quaranta V. Laminin-332 cleavage by Matriptase alters motility parameters of prostate cancer cells. Gordon Research Conference on Plasminogen Activation and Extracellular Proteolysis, Feb 2010, Ventura, CA.
  17. Tripathi M., Nandana S., Yamashita H., Kirchhofer D. and Quaranta V. Cleavage of Laminin-332 by hepsin and its implications in the progression of prostate cancer. Vanderbilt-Ingram Cancer Center Retreat, Student Life center Vanderbilt University, May 2009, Nashville, TN.
  18. Tripathi M., Nandana S., Yamashita H., Ganesan R., Kirchhofer D. and Quaranta V. Proteolytic processing of laminin-332 by type II transmembrane serine protease hepsin, and its implications in prostate cancer. SBUR Fall Annual Meeting, Nov 2008, Phoenix, Arizona.
  19. Yamashita H., Harris M., Tripathi M., Ronca F. and Quaranta V. The α3 LG4 module harbors a second binding site for Integrin α3β1 on Laminin-5. The 7th Annual Host-tumor Interactions Program & Department of Cancer Biology Joint Retreat, Nov 2007, Lake Barkley State Resort Park, Cadiz, Kentucky.
  20. Harris M., Yamashita H., Tripathi M., Quaranta V. Determining the mechanism of integrin-laminin binding. Matrix Biology, Volume 25, Supplement 1, November 2006, Page S83, American Society of Matrix Biology Biennial Meeting, 2006.
  21. Harris M., Yamashita H., Tripathi M. and Quaranta V. Determining the mechanism of integrin-laminin binding. The 5th Annual Host-tumor Interactions Program & Department of Cancer Biology Joint Retreat, Lake Barkley State Resort Park, Nov 2005, Cadiz, Kentucky.

 


Pathology and Therapeutics Flyer